For readers interested in a broader perspective on China’s pharmaceutical industry in global markets, our related analysis China Pharmaceutical Export Trends and Global Pharmaceutical Market Opportunities provides further insights into the evolving landscape of China’s pharmaceutical exports.

Key Therapeutic Areas Continue to Dominate Deal Activity

Looking at therapeutic areas, outbound licensing deals in Q1 2026 remained concentrated in several globally competitive fields.

Public data show:

● 15 deals exceeded $1 billion in total value

● Total potential deal value surpassed $54 billion

Investment continues to focus primarily on three major areas:

● GLP-1 therapies for metabolic diseases

● ADC (antibody-drug conjugates)

● Bispecific antibodies

These areas have already moved from proof-of-concept to industrial validation, making it easier for multinational pharmaceutical companies to evaluate their clinical value and commercial potential. Meanwhile, Chinese companies have accumulated extensive pipelines and clinical resources in these fields, making them an important source of global partnerships.

GLP-1: Continued Expansion of the Metabolic Disease Market

GLP-1 therapies remain one of the most closely watched areas in the global pharmaceutical industry.

With the number of patients suffering from obesity and metabolic disorders continuing to rise, the global GLP-1 market is still expanding rapidly. Multinational pharmaceutical companies are actively developing next-generation products, including biased GLP-1 therapies, multi-target GLP-1 drugs, and oral small-molecule GLP-1 treatments.

In this process, Chinese companies are demonstrating advantages in development speed and pipeline depth, positioning themselves as increasingly important participants in global GLP-1 research.

ADC: One of the Most Stable Outbound Innovation Assets

Among all innovative drug categories, ADCs remain one of the most consistent areas for Chinese outbound licensing.

Data show that more than 50% of global ADC clinical trials involve Chinese pharmaceutical companies. At the same time, several major multinational pharmaceutical companies have already established multiple licensing partnerships with Chinese firms in this field.

Chinese companies have developed clear advantages in ADC development, including:

● Extensive pipeline reserves

● Rapid clinical development progress

● Efficient R&D capabilities

As oncology treatment evolves toward combination approaches such as immunotherapy plus ADC, the importance of Chinese ADC assets in global collaboration continues to increase.

Bispecific Antibodies: A Consistent Source of Innovation

The bispecific antibody sector continues to show stable growth.

In the first quarter of 2026, three Chinese bispecific antibody projects completed international licensing deals, with a combined transaction value exceeding $8 billion.

Among them, innovative mechanisms such as PD-(L)1/VEGF bispecific antibodies are gradually becoming an important direction in global oncology research. After years of technological development, Chinese companies have already established a relatively complete pipeline ecosystem in this area.

RNA-Based Therapies Emerging as a New Growth Driver

Beyond established therapeutic areas, emerging technology platforms are also becoming an important driver of outbound innovation.

RNA-based therapeutics have been one of the most closely watched sectors in the global pharmaceutical industry in recent years. In 2025 alone, the total disclosed value of partnerships in the RNA therapeutics sector exceeded $27 billion, covering multiple technological approaches, including:

● siRNA

● ASO

● microRNA

Major international pharmaceutical companies continue to increase their investments in this field, including Novartis, Eli Lilly and Company, Sanofi, Biogen, and Novo Nordisk.

This trend has also opened new opportunities for Chinese companies. In recent years, more Chinese biotechnology firms have appeared in global RNA therapeutics partnership lists.

The momentum accelerated further in 2026. During the first quarter alone, Chinese companies completed three major RNA therapeutics licensing deals, with a total value exceeding $6.9 billion, surpassing the combined total of the previous five years.

These projects are mainly focused on:

● MASH (Metabolic Dysfunction-Associated Steatohepatitis)

● Hyperlipidemia

● Other chronic metabolic diseases

These disease areas involve large patient populations and clear commercialization pathways, making them well suited to China’s advantages in clinical resources and development efficiency.

At the same time, RNA therapeutics collaborations are increasingly shifting toward platform-based partnerships, rather than focusing solely on individual assets.

Conclusion: China’s Innovative Drug Globalization Enters a New Phase

Overall, the globalization of China’s innovative pharmaceutical sector is undergoing a structural upgrade.

In the past, international partnerships were primarily centered on single-asset licensing. Today, more collaborations are built around technology platforms, R&D capabilities, and long-term co-development.

This shift indicates that Chinese pharmaceutical companies are gradually transitioning from suppliers within the global pharmaceutical value chain to active participants in the global innovation ecosystem.

As R&D capabilities continue to improve and international collaborations deepen, Chinese innovative assets are likely to play an even more significant role in the global pharmaceutical market. For Chinese pharmaceutical distributor DengYueMed, this trend also represents growing opportunities to connect Chinese innovative medicines with healthcare markets around the world.